Medivation (Medivation) Days Sales Outstanding : 0.00 (As of Jun. 2016)

View and export this data going back to 1996. Start your Free Trial

What is Medivation Days Sales Outstanding?

Medivation's average Accounts Receivable for the three months ended in Jun. 2016 was $0 Mil. Medivation's Revenue for the three months ended in Jun. 2016 was $206 Mil. Hence, Medivation's Days Sales Outstanding for the three months ended in Jun. 2016 was 0.00.

The historical rank and industry rank for Medivation's Days Sales Outstanding or its related term are showing as below:

MDVN's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.245
* Ranked among companies with meaningful Days Sales Outstanding only.

Medivation's Days Sales Outstanding stayed the same from Jun. 2015 (0.00) to Jun. 2016 (0.00).

Medivation Days Sales Outstanding Historical Data

The historical data trend for Medivation's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivation Days Sales Outstanding Chart

Medivation Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Days Sales Outstanding

Get a 7-Day Free Trial

Medivation Quarterly Data
	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Medivation's Days Sales Outstanding

For the Biotechnology subindustry, Medivation's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medivation's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivation's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Medivation's Days Sales Outstanding falls into.

Medivation Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Medivation's Days Sales Outstanding for the fiscal year that ended in Dec. 2015 is calculated as

	Days Sales Outstanding (A: Dec. 2015 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2014 )	+	Accounts Receivable (A: Dec. 2015 ))	/	count )	/	Revenue (A: Dec. 2015 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	943.258	*	365
=	0					/	943.258	*	365
=	0.00

Medivation's Days Sales Outstanding for the quarter that ended in Jun. 2016 is calculated as:

	Days Sales Outstanding (Q: Jun. 2016 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2016 )	+	Accounts Receivable (A: Jun. 2016 ))	/	count )	/	Revenue (A: Jun. 2016 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	206.165	*	365 / 4
=	0					/	206.165	*	365 / 4
=	0.00

Medivation (NAS:MDVN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Medivation Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Medivation's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivation (Medivation) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivation Inc (NAS:MDVN) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.medivation.com/

Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Executives

W Anthony Vernon	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, NEW YORK NY 10018
Marion Mccourt	officer: Chief Operating Officer	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Tseli Lily Yang	officer: VP, Finance and Accounting	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Mohammad Hirmand	officer: Interim Chief Medical Officer	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
David Hung	director, officer: President and CEO	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Wendy L Yarno	director
Jennifer Jarrett	officer: Chief Financial Officer	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Kim D Blickenstaff	director	C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
Powell Andrew Kenneth William	officer: SVP, General Counsel & Crp Sec	C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Rick Bierly	officer: CFO (former)	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Joseph M Lobacki	officer: Chief Commercial Officer	C/O MICROMET, INC., 9201 CORPORATE BLVD., SUITE 400, ROCKVILLE MD 20850
Jennifer J Rhodes	officer: GC & Corporate Secretary	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608